Year-end cheer: India closer to COVID vaccine after UK nod
COVID-19, News

Year-end cheer: India closer to COVID vaccine after UK nod

December 31, 2020

Expert panel to reconvene and further deliberate on vaccine approval tomorrow

New Delhi: The United Kingdom (UK) yesterday approved Coronavirus vaccine developed by University of Oxford and AstraZeneca, paving way for its rollout at a time when the country is in the grip of its worst wave of infections, and offering an important endorsement that will likely be taken into account in India, where authorities are reviewing the inoculation.

While the UK said it will begin administering the first shots from next week, Indians must wait a little longer since the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) – which is vetting the data from safety and efficacy trials – is yet to reach a decision.

The CDSCO that met last afternoon to consider emergency use authorisation applications by the Serum Institute of India (SII) for the Oxford COVID-19 vaccine and Bharat Biotech’s Covaxin will reconvene on Jan. 1 to further deliberate on the matter.

The SEC on Covid-19 deliberated and analysed the additional data and information submitted by SII and Bharat Biotech.”The SEC in the CDSCO met in the afternoon to consider the emergency use authorisation (EUA) request of Pfizer, SII and Bharat Biotech Pvt. Ltd,” the Health Ministry said.

“Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech was perused and analysed by the SEC. The analysis of the additional data and information is going on. The SEC will convene again on Jan. 1, 2021,” it said.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) on Wednesday approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.

READ ALSO  Health Officers hold dry run to face third wave

The Pune-based Serum Institute of India, the world’s largest vaccine manufacturer, has entered into a tie-up AstraZeneca to manufacture Covishield. Incidentally, the Phase II clinical trials for Covishield were conducted at JSS Medical College and Hospital in Mysuru in August this year. 

In Karnataka, JSS Hospital is the only institute that has been selected for the clinical trial. Covishield was administered to about 25 volunteers at JSS Hospital after Phase II trials began on Aug. 29. 

ABOUT

Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 45 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.

CONTACT

Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Online Edition: [email protected]
Print Editon: [email protected]
For News/Press Release: [email protected]